T-cell Surface Glycoprotein CD4 (CD4) Antibody |
abx231475-100ug |
Abbexa |
100 ug |
EUR 610.8 |
|
Human IgG antibody Laboratories manufactures the spike-specific cd4 t-cell sars test reagents distributed by Genprice. The Spike-Specific Cd4 T-Cell Sars Test reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Test. Other Spike-Specific products are available in stock. Specificity: Spike-Specific Category: Cd4 Group: T-Cell Sars
T-cell Surface Glycoprotein CD4 (CD4) Antibody |
Abbexa |
0.2 mg |
EUR 886.8 |
|
T-cell Surface Glycoprotein CD4 (CD4) Antibody |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 218.40
-
EUR 376.80
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
T-cell Surface Glycoprotein CD4 (CD4) Antibody |
Abbexa |
0.25 mg |
EUR 710.4 |
|
T-cell Surface Glycoprotein CD4 (CD4) Antibody |
Abbexa |
0.25 mg |
EUR 678 |
|
T-cell Surface Glycoprotein CD4 (CD4) Antibody |
Abbexa |
0.25 mg |
EUR 678 |
|
T-cell Surface Glycoprotein CD4 (CD4) Antibody |
Abbexa |
1 mg |
EUR 994.8 |
|
T-cell Surface Glycoprotein CD4 (CD4) Antibody |
Abbexa |
0.25 mg |
EUR 678 |
|
T-Cell Sars information
SARS-CoV Spike Antibody |
3221-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3223-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3223-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
anti- Kv1.4-Specific antibody |
FNab04664 |
FN Test |
100µg |
EUR 606.3 |
|
Description: Antibody raised against Kv1.4-Specific |
anti- TUBB3 specific antibody |
FNab09890 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against TUBB3 specific |
anti- REDD1 specific antibody |
FNab07228 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against REDD1 specific |
anti- TDRKH specific antibody |
FNab08580 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against TDRKH specific |
SARS-CoV-2 Spike Peptide |
9083P |
ProSci |
0.05 mg |
EUR 235.5 |
Description: (NT) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike Peptide |
9087P |
ProSci |
0.05 mg |
EUR 235.5 |
Description: (CT) SARS-CoV-2 Spike RBD peptide |
SARS-CoV-2 Spike Peptide |
9091P |
ProSci |
0.05 mg |
EUR 235.5 |
Description: (IN) SARS-CoV-2 Spike peptide |
SARS-CoV-2 Spike Peptide |
9095P |
ProSci |
0.05 mg |
EUR 235.5 |
Description: (IN) SARS-CoV-2 Spike peptide |
anti- SCN9A/Nav1.7-Specific antibody |
FNab07646 |
FN Test |
100µg |
EUR 702 |
|
Description: Antibody raised against SCN9A/Nav1.7-Specific |
anti- Claudin 4-specific antibody |
FNab01739 |
FN Test |
100µg |
EUR 606.3 |
|
Description: Antibody raised against Claudin 4-specific |
anti- Claudin 9-specific antibody |
FNab01741 |
FN Test |
100µg |
EUR 606.3 |
|
Description: Antibody raised against Claudin 9-specific |
Spike (SARS-CoV-2) Lentivirus |
78010-1 |
BPS Bioscience |
100 µl |
EUR 835 |
Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_ |